Fragen und Thesen zu medikamentösen Behandlungsoptionen der Alzheimer-Demenz mit Acetylcholinesterase-Hemmern

Standard

Fragen und Thesen zu medikamentösen Behandlungsoptionen der Alzheimer-Demenz mit Acetylcholinesterase-Hemmern. / Bussche van den, Hendrik.

in: Z GERONTOL GERIATR, Jahrgang 38 Suppl 1, 09.2005, S. I18-20.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{cec5b8457b3949d5bb973c208172fcaf,
title = "Fragen und Thesen zu medikament{\"o}sen Behandlungsoptionen der Alzheimer-Demenz mit Acetylcholinesterase-Hemmern",
abstract = "The paper reviews the evidence for the recommendation of cholinesterase inhibitors and asks critical questions concerning the reasons for the discrepancy between the weak evidence and the recommendation of these drugs in therapy guidelines. Furthermore, the argument of the severe underuse of these drugs is examined.",
keywords = "Alzheimer Disease, Cholinesterase Inhibitors, Evidence-Based Medicine, Humans, Practice Guidelines as Topic, Practice Patterns, Physicians', Randomized Controlled Trials as Topic, Treatment Outcome",
author = "{Bussche van den}, Hendrik",
year = "2005",
month = sep,
doi = "10.1007/s00391-005-1105-0",
language = "Deutsch",
volume = "38 Suppl 1",
pages = "I18--20",
journal = "Z GERONTOL GERIATR",
issn = "0948-6704",
publisher = "D. Steinkopff-Verlag",

}

RIS

TY - JOUR

T1 - Fragen und Thesen zu medikamentösen Behandlungsoptionen der Alzheimer-Demenz mit Acetylcholinesterase-Hemmern

AU - Bussche van den, Hendrik

PY - 2005/9

Y1 - 2005/9

N2 - The paper reviews the evidence for the recommendation of cholinesterase inhibitors and asks critical questions concerning the reasons for the discrepancy between the weak evidence and the recommendation of these drugs in therapy guidelines. Furthermore, the argument of the severe underuse of these drugs is examined.

AB - The paper reviews the evidence for the recommendation of cholinesterase inhibitors and asks critical questions concerning the reasons for the discrepancy between the weak evidence and the recommendation of these drugs in therapy guidelines. Furthermore, the argument of the severe underuse of these drugs is examined.

KW - Alzheimer Disease

KW - Cholinesterase Inhibitors

KW - Evidence-Based Medicine

KW - Humans

KW - Practice Guidelines as Topic

KW - Practice Patterns, Physicians'

KW - Randomized Controlled Trials as Topic

KW - Treatment Outcome

U2 - 10.1007/s00391-005-1105-0

DO - 10.1007/s00391-005-1105-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 16189731

VL - 38 Suppl 1

SP - I18-20

JO - Z GERONTOL GERIATR

JF - Z GERONTOL GERIATR

SN - 0948-6704

ER -